110P Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC

B.C. Cho,C-H. Chiu, E. Massarelli,S.P. Chawla, G.L. Buchschacher, K. Goto,S-W. Kim, T.R. Overbeck,H.H.F. Loong, C.E. Chee,P. Garrido, S. Heinzmann, B. Pitcher,T. John

ANNALS OF ONCOLOGY（2022）

引用 0|浏览6

暂无评分

摘要

Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are oncogenic drivers in many solid tumours, including NSCLC. Entrectinib (a CNS-active, potent TRK inhibitor) has shown efficacy in pts with NTRK-fp NSCLC from the STARTRK-2 (NCT02568267) and STARTRK-1 (NCT02097810) trials: objective response rate (ORR) was 69% (n=9/13; 31 Oct 2018 cutoff). We present an updated analysis in this cohort.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要